{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:50:06Z","timestamp":1784307006332,"version":"3.55.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cluster of differentiation 99 (CD99) is a receptor that is significantly upregulated in acute myeloid leukemia (AML). FMS-like tyrosine kinase 3 internal tandem duplication mutation in AML (FLT3-ITD AML) exhibits even higher levels of CD99 expression. Our group previously employed a novel peptide platform technology called elastin-like polypeptides and fused it with single-chain antibodies capable of binding to FLT3 (FLT3-A192) or CD99 (CD99-A192). Targeting either FLT3 or CD99 using FLT3-A192 or CD99-A192 led to AML cell death and reduced leukemia burden in AML mouse models. Here, we report on the development of a novel Co-Assembled construct that is capable of binding to both CD99 and FLT3 and the antileukemia activity of the bispecific construct in FLT3-ITD AML preclinical models. This dual-targeting Co-Assembled formulation exhibits cytotoxic effects on AML cells (AML cell lines and primary blasts), reduced leukemia burden and prolonged survival in FLT3-ITD AML mouse models. Altogether, this study demonstrates the potential of an innovative therapeutic strategy that targets both FLT3 and CD99 in FLT3-ITD AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study investigates a dual-targeting strategy in acute myeloid leukemia (AML), focusing on FLT3 and CD99. The approach demonstrates enhanced therapeutic potential, presenting a novel option for AML treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0096","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:39:16Z","timestamp":1721025556000},"page":"1946-1962","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["FLT3\/CD99 Bispecific Antibody\u2013Based Nanoparticles for Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-887X","authenticated-orcid":false,"given":"Atham","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-5166","authenticated-orcid":false,"given":"Alvin","family":"Phan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, University of Southern California, Los Angeles, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9175-3558","authenticated-orcid":false,"given":"Vijaya","family":"Vaikari","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-4600","authenticated-orcid":false,"given":"Mincheol","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, University of Southern California, Los Angeles, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7425-8800","authenticated-orcid":false,"given":"Mateusz","family":"Pospiech","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5797-6185","authenticated-orcid":false,"given":"Ryan","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3747-116X","authenticated-orcid":false,"given":"Yiting","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-1654","authenticated-orcid":false,"given":"J. Andrew","family":"MacKay","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, University of Southern California, Los Angeles, California. 2"},{"name":"Department of Ophthalmology, USC Roski Eye Institute, USC Keck School of Medicine, University of Southern California, Los Angeles, California. 4"},{"name":"Department of Biomedical Engineering, USC Viterbi School of Engineering, University of Southern California, Los Angeles, California. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5567-5521","authenticated-orcid":false,"given":"Houda","family":"Alachkar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, California. 1"},{"name":"USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"2025032818115701400_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025032818115701400_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025032818115701400_bib3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"2025032818115701400_bib4","article-title":"Cancer stat facts: acute myeloid leukemia","author":"National Cancer Institute, SEER","year":"2023  16"},{"key":"2025032818115701400_bib5","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"2025032818115701400_bib6","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota","year":"1997","journal-title":"Leukemia"},{"key":"2025032818115701400_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment","volume":"2006","author":"Small","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025032818115701400_bib8","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"2025032818115701400_bib9","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"2025032818115701400_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025032818115701400_bib11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"2025032818115701400_bib12","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"2025032818115701400_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"2025032818115701400_bib14","doi-asserted-by":"crossref","first-page":"107844","DOI":"10.1016\/j.pharmthera.2021.107844","article-title":"Strategies targeting FLT3 beyond the kinase inhibitors","volume":"225","author":"Almatani","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2025032818115701400_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025032818115701400_bib16","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/j.1460-2075.1989.tb08485.x","article-title":"The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product","volume":"8","author":"Gelin","year":"1989","journal-title":"EMBO J"},{"key":"2025032818115701400_bib17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI36667","article-title":"CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis","volume":"120","author":"Rocchi","year":"2010","journal-title":"J Clin Invest"},{"key":"2025032818115701400_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4049\/jimmunol.154.1.26","article-title":"The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes","volume":"154","author":"Bernard","year":"1995","journal-title":"J Immunol"},{"key":"2025032818115701400_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-2478(99)00165-0","article-title":"CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway","volume":"71","author":"Kasinrerk","year":"2000","journal-title":"Immunol Lett"},{"key":"2025032818115701400_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.166.2.787","article-title":"CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface","volume":"166","author":"Sohn","year":"2001","journal-title":"J Immunol"},{"key":"2025032818115701400_bib21","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.4049\/jimmunol.158.6.2543","article-title":"Apoptosis of immature thymocytes mediated by E2\/CD99","volume":"158","author":"Bernard","year":"1997","journal-title":"J Immunol"},{"key":"2025032818115701400_bib22","doi-asserted-by":"crossref","first-page":"eaaj2025","DOI":"10.1126\/scitranslmed.aaj2025","article-title":"CD99 is a therapeutic target on disease stem cells in myeloid malignancies","volume":"9","author":"Chung","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025032818115701400_bib23","first-page":"1067","article-title":"Overexpression of the pseudoautosomal gene MIC2 in Ewing\u2019s sarcoma and peripheral primitive neuroectodermal tumor","volume":"5","author":"Kovar","year":"1990","journal-title":"Oncogene"},{"key":"2025032818115701400_bib24","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U","article-title":"MIC2 is a specific marker for Ewing\u2019s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing\u2019s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration","volume":"67","author":"Ambros","year":"1991","journal-title":"Cancer"},{"key":"2025032818115701400_bib25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3324\/haematol.2018.207001","article-title":"Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia","volume":"105","author":"Vaikari","year":"2020","journal-title":"Haematologica"},{"key":"2025032818115701400_bib26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/s41375-022-01566-5","article-title":"CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML","volume":"36","author":"Travaglini","year":"2022","journal-title":"Leukemia"},{"key":"2025032818115701400_bib27","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1182\/blood-2011-07-365726","article-title":"SRC is a signaling mediator in FLT3-ITD\u2013 but not in FLT3-TKD\u2013positive AML","volume":"119","author":"Leischner","year":"2012","journal-title":"Blood"},{"key":"2025032818115701400_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.biocel.2018.12.007","article-title":"The role of SRC family kinases in FLT3 signaling","volume":"107","author":"Kazi","year":"2019","journal-title":"Int J Biochem Cell Biol"},{"key":"2025032818115701400_bib29","doi-asserted-by":"crossref","first-page":"108332","DOI":"10.1016\/j.celrep.2020.108332","article-title":"GDF6-CD99 signaling regulates Src and Ewing sarcoma growth","volume":"33","author":"Zhou","year":"2020","journal-title":"Cell Rep"},{"key":"2025032818115701400_bib30","doi-asserted-by":"crossref","first-page":"102236","DOI":"10.1016\/j.nano.2020.102236","article-title":"Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia","volume":"29","author":"Vaikari","year":"2020","journal-title":"Nanomedicine"},{"key":"2025032818115701400_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2020.05.021","article-title":"Anti-FLT3 nanoparticles for acute myeloid leukemia: preclinical pharmacology and pharmacokinetics","volume":"324","author":"Park","year":"2020","journal-title":"J Control Release"},{"key":"2025032818115701400_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2014.06.028","article-title":"Applications of elastin-like polypeptides in drug delivery","volume":"190","author":"MacEwan","year":"2014","journal-title":"J Control Release"},{"key":"2025032818115701400_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/088391159100600306","article-title":"Biocompatibility of the bioelastic materials, poly(GVGVP) and its \u03b3-irradiation cross-linked matrix: summary of generic biological test results","volume":"6","author":"Urry","year":"1991","journal-title":"J Bioact Compat Polym"},{"key":"2025032818115701400_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/1389201011314040011","article-title":"Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing\u2019s sarcoma tumor cells","volume":"14","author":"Gellini","year":"2013","journal-title":"Curr Pharm Biotechnol"},{"key":"2025032818115701400_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/bies.950030108","article-title":"Methionine or not methionine at the beginning of a protein","volume":"3","author":"Sherman","year":"1985","journal-title":"Bioessays"},{"key":"2025032818115701400_bib36","doi-asserted-by":"crossref","first-page":"120338","DOI":"10.1016\/j.biomaterials.2020.120338","article-title":"Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma","volume":"262","author":"Lee","year":"2020","journal-title":"Biomaterials"},{"key":"2025032818115701400_bib37","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/nar\/gkg563","article-title":"ExPASy: the proteomics server for in-depth protein knowledge and analysis","volume":"31","author":"Gasteiger","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2025032818115701400_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1039\/C0AN00738B","article-title":"Characterizing the size, shape, and compactness of a polydisperse prolate ellipsoidal particle via quadruple-detector hydrodynamic chromatography","volume":"136","author":"Brewer","year":"2011","journal-title":"Analyst"},{"key":"2025032818115701400_bib39","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev"},{"key":"2025032818115701400_bib40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-01-0195","article-title":"Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"key":"2025032818115701400_bib41","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"key":"2025032818115701400_bib42","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"2025032818115701400_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"2025032818115701400_bib44","first-page":"5134","article-title":"CD99 engagement: an effective therapeutic strategy for Ewing tumors","volume":"60","author":"Scotlandi","year":"2000","journal-title":"Cancer Res"},{"key":"2025032818115701400_bib45","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V99.11.3885","article-title":"A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo","volume":"99","author":"Levis","year":"2002","journal-title":"Blood"},{"key":"2025032818115701400_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.11.010","article-title":"Elastin-like polypeptides: therapeutic applications for an emerging class of nanomedicines","volume":"240","author":"Despanie","year":"2016","journal-title":"J Control Release"},{"key":"2025032818115701400_bib47","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1074\/jbc.M111.311522","article-title":"Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains","volume":"287","author":"Hutt","year":"2012","journal-title":"J Biol Chem"},{"key":"2025032818115701400_bib48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.leu.2403303","article-title":"CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease","volume":"18","author":"Dworzak","year":"2004","journal-title":"Leukemia"},{"key":"2025032818115701400_bib49","first-page":"238","article-title":"Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells","volume":"10","author":"Rosnet","year":"1996","journal-title":"Leukemia"},{"key":"2025032818115701400_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jso.23109","article-title":"Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients","volume":"106","author":"Kato","year":"2012","journal-title":"J Surg Oncol"},{"key":"2025032818115701400_bib51","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/ncomms5770","article-title":"Recurrent CDC25C mutations drive malignant transformation in FPD\/AML","volume":"5","author":"Yoshimi","year":"2014","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0096\/3474939\/crc-24-0096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/8\/1946\/3502925\/crc-24-0096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/8\/1946\/3502925\/crc-24-0096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:35:22Z","timestamp":1743190522000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/8\/1946\/746895\/FLT3-CD99-Bispecific-Antibody-Based-Nanoparticles"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0096","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.26510592","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510583.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510580.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510610.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510598.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510601","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781102.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781105.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688749","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27157956","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510592.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510595.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781105","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510601.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781099.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510583","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510595","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688752","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510598.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510610.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510604.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510604","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27157953","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510589.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510607.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781099","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510595.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510586.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781108","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510601.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510577.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510586","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510598","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510604.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510607","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510607.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27157962","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510577.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510610","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510577","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510589","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28688746","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27157959","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781108.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26781102","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26510580","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7391952","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7391952.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}